iSAM Funds UK Ltd Makes New $1.55 Million Investment in Danaher Co. (NYSE:DHR)

iSAM Funds UK Ltd bought a new position in shares of Danaher Co. (NYSE:DHR) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 5,568 shares of the conglomerate’s stock, valued at approximately $1,548,000. Danaher comprises approximately 0.9% of iSAM Funds UK Ltd’s portfolio, making the stock its 21st largest position.

Other large investors also recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Danaher during the 2nd quarter worth about $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the 3rd quarter valued at about $40,000. Finally, FSA Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth approximately $50,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Thursday. Stifel Nicolaus raised their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Evercore ISI raised their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. KeyCorp raised their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird reduced their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $287.16.

Danaher Stock Performance

Danaher stock opened at $230.12 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a fifty day moving average of $251.66 and a two-hundred day moving average of $258.69. The company has a market capitalization of $166.21 billion, a price-to-earnings ratio of 43.92, a PEG ratio of 4.35 and a beta of 0.83. Danaher Co. has a fifty-two week low of $215.68 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 earnings per share. On average, analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.